Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM52NOI)

Drug Name
NSC-656158 Drug Info
Synonyms
CHM-1; NSC-656158; 154554-41-3; CHM 1; CHM-1 hydrate; CHEMBL280099; 6-(2-Fluorophenyl)[1,3]dioxolo[4,5-G]quinolin-8(5h)-One; 1,3-Dioxolo[4,5-g]quinolin-8(5H)-one, 6-(2-fluorophenyl)-; NSC656158; AC1Q4OOR; AC1L8C3G; Neuro_000375; SCHEMBL338729; CTK7C2351; AOB2618; DTXSID80327429; MolPort-009-194-114; HMS3262E04; ZINC5581788; KS-00002WS1; Tox21_500741; BDBM50041119; AKOS015994545; LP00741; CE-0108; NCGC00261426-01; NCGC00186026-01; NCI60_019422; J-009113; 1,5-g]quinolin-8(5H)-one, 6-(2-fluorophenyl)-; BRD-K94145482-001-02-8
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
375860
CAS Number
CAS 154554-41-3
TTD Drug ID
DM52NOI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Stress-activated protein kinase JNK3 (JNK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [2]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [2]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [2]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [2]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [2]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [2]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [2]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [2]
PMID25991433-Compound-J2 DMZSOCK N. A. N. A. Patented [2]
7-azaindole derivative 3 DMQ7BV4 N. A. N. A. Patented [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type A (MAO-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [3]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [4]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [5]
Isocarboxazid DMAF1NB Depression 6A70-6A7Z Approved [6]
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [7]
Psoralen DMIZJ8M N. A. N. A. Phase 3 [8]
CHF-3381 DMQ2O8V Neuropathic pain 8E43.0 Phase 2 [9]
Ladostigil DMJSY3Q Alzheimer disease 8A20 Phase 2 [10]
CX157 DMS2WB5 Mood disorder 6A60-6E23 Phase 2 [11]
PIPERINE DMYEAB1 Vitiligo ED63.0 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [1]
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [1]

References

1 Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumo... J Med Chem. 2010 Feb 25;53(4):1616-26.
2 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
3 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
4 Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
5 Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
6 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
7 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
8 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
9 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
10 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
11 Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
12 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.